🧬 Barry Ticho - Part 3 | Lessons From Rigorous Drug Development | Industry vs. Academic Research Standards | A Patient-Centered Approach to Clinical Trials | How RNA is Shaping Modern Medicine

The Biotech Startups Podcast

The Biotech Startups Podcast, brought to you by Excedr—empowering life science startups with founder-friendly equipment leasing to fast-track R&D and drive commercialization success.

Know someone in need of lab equipment? Join Excedr’s referral program: Give your friends $1,000 and earn $1,000 for every qualified referral! 💸

Get your unique referral link here: refer.excedr.com/ZTHETY.

Part 3 of 4: Jon Chee hosts Barry Ticho, Founder of Verve Therapeutics and Chief Medical Officer at Stoke Therapeutics, a biotech company addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines.

With an MD PhD from the University of Chicago and extensive experience across academia and industry, Barry brings over two decades of expertise in clinical development. His journey includes roles as Head of Development at Moderna, Head of External R&D Innovation at Pfizer, and VP of Clinical Development at Biogen, where he's been instrumental in advancing numerous therapeutic programs across multiple disease areas.

Barry's unique perspective spanning academic medicine and biotechnology innovation makes his insights invaluable for aspiring leaders in the field.

Join us this week to hear about:

• Barry’s switch from academia to industry, and the challenges of his role at Merck
• Navigating drug development and the rigorous standards of pharmaceutical research
• Leading patient-centered clinical development at Biogen to create impactful therapies
• Exploring the potential of RNA medicine at Pfizer and Moderna
• Working on Moderna’s lipid nanoparticle technology, the basis for the COVID-19 vaccine

Please enjoy Jon’s conversation with Barry Ticho.

Subscribe to the podcast: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994

Find Our Guest, Barry Ticho, at these links:

https://www.linkedin.com/in/barryticho/

https://www.stoketherapeutics.com/

https://www.vervetherapeutics.com/

Find Our Host, Jon Chee, at these links:

https://www.linkedin.com/in/jonchee

https://www.excedr.com

Excedr Socials & Website

LinkedIn: https://www.linkedin.com/company/excedr/

Youtube: https://www.youtube.com/@excedr

Instagram: https://www.instagram.com/excedr_inc

Twitter: https://twitter.com/ExcedrInc

Facebook: https://www.facebook.com/excedr

TikTok: https://www.tiktok.com/@excedr

Podcast Website: https://www.thebiotechstartupspodcast.com/

Topics Mentioned:

Merck: https://www.merck.com/

Biogen: https://www.biogen.com/

Pfizer: https://www.pfizer.com/

Wave Biosciences: https://wavelifesciences.com/

Moderna: https://www.modernatx.com/en-US

Verve Therapeutics: https://www.vervetx.com/

People Mentioned:

Stéphane Bancel: https://www.linkedin.com/in/st%C3%A9phane-bancel-8185251

Timestamps:

00:00 Intro

02:06 Transitioning from academia to Merck

03:41 Rigorous drug development processes at Merck

06:00 Industry vs. academia: reproducibility and research quality in pharma

08:35 Patient-centered clinical trials at Biogen

09:45 Phases of clinical trials and ensuring patient access

14:06 Challenges in drug approval: biology, regulations, and precision medicine

18:24 Biogen’s focus on impactful therapies for severe diseases

23:14 Joining Pfizer for cardiovascular research and RNA exploration

27:04 Exploring RNA therapeutics at Pfizer and transitioning to Moderna

30:21 Driving lipid nanoparticle breakthroughs at Moderna

36:23 Outro

The Biotech Startups Podcast is handcrafted by our friends over at: fame.so